:quality(85)/cloudfront-us-east-1.images.arcpublishing.com/infobae/W7G32IMQRFCK3DW2RYMVY3KPNI.jpg)
if something synthesizes endemic immunity to a region—that is, an evil that habitually and repeatedly affects a region, region, or country—is Dengue.
argentina still lives worst dengue epidemic With 129,595 registered cases and 65 deaths so far in 2023, according to the National Epidemiology Bulletin, week 30. Although the actual number of people infected with a mosquito-borne disease aedes aegyptiThere could be more than 300,000, as many cases occur without symptoms or being registered in the system.
On April 26 this year, the National Drug, Food and Medical Technology Administration (allowed, Quadrivalent dengue vaccine approved for useDeveloped by Japanese laboratory Takeda, This vaccine is also known as cudengaWill be for people above 4 years of age, regardless of whether they have had the disease before or not.
As Infobey learned, Takeda Laboratory confirmed that the dengue vaccine will be available for use in the spring., The Japanese lab started the production process months ago and is working to reduce production and delivery times.
Also according to expert infectious disease experts dengue broken down with seasonal and more classic endemic areas : It is no longer a disease concentrated in the high temperature period of summer, but its transmission can survive throughout the year. Something that is slowly being driven by the effects of climate change and its continued existence of “refuges” for more viruses, bacteria, fungi, and zoonotic diseases – those transmitted from animals to humans.
Currently, dengue cases are found in cities across the country. According to the official information of the Ministry of National Health, Classic Endemic Regions of Argentina The main ones in Dengue are Jujuy, Salta, Tucumán, Santiago del Estero, Corrientes, Chaco and Catamarca.
Formula Immunizer developed by Japanese lab represents a revolutionary change In the therapeutic approach to dengue, especially in the prevention of severe symptoms.
Dengue is a flu-like viral illness that is usually mild but can cause fatal complications. There are no antivirals or specific treatments, and it is estimated that 20,000 to 25,000 people, mainly children, die from the virus each year.
The doctor said, “The advent of new vaccines always opens up the hope of being able to stop a disease and basically stop its most severe effects, especially in cases that may require hospitalization and be life-threatening.” I might fall in.” Pablo Bonvehi, Head of Infectious Diseases of CEMIC University Hospital, when he learned about ANMAT’s approval.
“It is important to mention that this new vaccine will be a fundamental tool in dengue prevention along with other measures we already know, such as The purpose of such actions is to prevent mosquitoes from finding suitable areas for breeding. And those who work to protect people from its bites,” he said. infobae Infectious disease doctor Bonvehi.
Complete plan of quadrivalent vaccine cudenga Involved two doses Of 0.5 ml, separated by an interval of three monthsWithout the need for confirmatory blood tests prior to its application.
based on a vaccine called TAK-003 Live attenuated dengue 2 virus with added DNA from the other three serotypesProvides protection against four serotypes of the disease.
in detail infobaeAccording to clinical trials, the vaccine displayed an overall efficacy of 80.2% in preventing symptomatic dengue cases within 12 months of application. In addition, Qudenga achieved an important endpoint of preventing 90.4% of hospitalizations at 18 months after vaccination.
The first approval for the Qudenga vaccine was received in Indonesia in August 2022, followed by the European Union, the United Kingdom and Brazil.
called strong clinical studies High tide of which include more than the results of the Cudenga vaccine 20 thousand healthy participants from endemic areas, with a follow-up of 4.5 years, where the vaccine resulted in an 84% reduction in the number of dengue hospitalizations and a 61% reduction in symptomatic dengue cases; With very good safety profile.
The full clinical program includes 19 studies that have already been completed and that are still in progress, making it the largest survey ever conducted for a pharmaceutical product by TEDA in its two and a half century history. represents.
The vaccine is based on a live attenuated virus developed from dengue serotype 2, which provides the genetic ‘backbone’ for all four serotypes and is designed to protect against any of them. As far as storage is concerned, it requires preservation in a refrigerator at a temperature between 2 to 8 °C.
In this regard, “The main transmitting agent of the disease is the Aedes aegypti mosquito,” said infectious disease specialist Analia Uruena, director of the Center for the Study of Prevention and Control of Communicable Diseases of the University of Isalud, said Dr. Analia Uruena, director. Study Center for the Prevention and Control of Communicable Diseases of the University of Islud. “The infection is caused by any one of the four dengue virus serotypes, each of which can cause dengue fever or severe dengue. Infection with any one of them does not confer protection against the remaining serotypes. He informed that this vaccine is quadrivalent and has been shown to generate a response against four serotypes.
This vaccine is contraindicated in pregnant women, lactating women and persons with weakened immunity. The most common side effects include pain and redness at the injection site, headache, muscle pain, malaise, and weakness.
from the Takeda laboratory, he reported that “currently, close to Half of the world is living in danger of dengue It is estimated to cause 390 million infections and approximately 20,000 deaths worldwide each year”, referring to views expressed by the World Health Organization (WHO) and the Pan American Health Organization (PAHO).
Despite the vaccine’s approval, health officials and experts stress the importance of continuing vector prevention and control measures.
The Pan American Health Organization (PAHO) is in talks with the Japanese pharmaceutical company Takeda. In this sense, Jarbas Barbosa, director of PAHO, stressed that the study data showed strong results, preventing 61% of dengue infections and 85% of severe cases.
Barbosa said that although a strategic group of the World Health Organization (WHO) may discuss the possibility of recommending a vaccine in the second half of 2023, PAHO has already started preliminary discussions with Takeda. worth of dosages. Brazil, Mexico and Colombia Improvements to lower prices can be achieved by agreeing to purchase through PAHO funds.
Angela Gentile, a renowned infectious disease specialist at the Ricardo Gutiérrez Hospital, recalled that “even when we have a vaccine to prevent it, we still have to abandon the already known measures to prevent the spread of the vector mosquito.” No. The most important of which are:
*Junk
* Removal of containers containing stagnant water
*Measures to avoid bites, such as use of repellent, loose clothing that protects arms and legs
* Installation of mosquito nets in homes
Dengue disease, although in some cases it may be asymptomatic, when it does express symptoms it presents with a acute and nonspecific febrile picture, It is so called because it is a condition lasting less than 7 days without respiratory symptoms. These symptoms are usually accompanied by severe headache, pain behind the eyes, muscle and joint pain, and sometimes diarrhea or vomiting; Sometimes a rash also appears on the skin.
“The development of the disease caused by dengue is related to the factors of the infected person and the way they react to the infection, the serotype infecting the person and the initial consultation,” said Eduardo López, head of the Department of Medicine. Ricardo Gutierrez Children’s Hospital. “The efficacy data shown by the Takeda clinical study is very compelling,” said Dr. Lopez.
Another vaccine being considered to prevent dengue is Dengvaxia, which is made from live weakened or attenuated microbes. This formula was developed by the Sanofi Pasteur laboratory; It is a quadrivalent vaccine that was produced using recombinant DNA technology It is dosed with a 3 dose schedule at 0, 6 and 12 months.
In Argentina, Dengvaxia was approved by regulator ANMAT in 2017., As stated in the process’s official document, which Infobay has accessed, it is being implemented “especially among people aged 9 to 45 years living in endemic areas caused by serotypes 1, 2, 3 and 4 of dengue virus.” was authorized to prevent dengue from occurring, noting that these zones would be established by the Ministry of Health from epidemiological data.
The medium consulted ANMAT sources, who specified that currently “the Dengvaxia vaccine is still authorized” in the country. In this regard, Florencia Esquivel, Medical Director of Sanofi Vaccines for Southern Cone, explained infobae: “In Argentina, Dengvaxia was approved by ANMAT in March 2017 with an indication of 9 to 45 years. Subsequently, an updated package insert was released that included a warning for people who do not have the disease. This update was approved by ANMAT in June 2020. The vaccine is currently indicated for people 6 to 45 years of age whose previous dengue infection has been confirmed by a test, with a 3-dose schedule at 0, 6, and 12 months.
keep reading: